Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SLC25A20 | O43772 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.76 |
| ▸ | GMNN | O75496 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitoyl-Carnitine SCHEMBL115183 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL19182624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL8050598 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL288242 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL17164609 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL25373354 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL187668 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2915508 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL188470 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL198686 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240047065-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | UNIVERSITY OF DUNDEE (GB) | 2024-02-08 | — | — | US | claimed |
| EP-4292102-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2023-12-20 | — | — | EP | claimed |
| WO-2022171680-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-08-18 | — | — | WO | claimed |
| EP-3490677-A1 | LIPID, PROTEIN, AND METABOLITE MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Berg LLC (US) | 2019-06-05 | — | — | EP | claimed |
| US-20180024132-A1 | LIPID, PROTEIN, AND METABOLITE MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BERG LLC | 2018-01-25 | — | — | US | claimed |
| WO-2018009834-A1 | LIPID, PROTEIN, AND METABOLITE MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BERG LLC (US) | 2018-01-11 | — | — | WO | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| EP-2449488-B1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2015-01-14 | — | — | EP | claimed |
| US-20120208282-A1 | Method For Normalization in Metabolomics Analysis Methods with Endogenous Reference Metabolites. | BIOCRATES LIFE SCIENCES AG | 2012-08-16 | — | — | US | claimed |
| US-20120136581-A1 | Method of Diagnosing Asphyxia | BIOCRATES LIFE SCIENCES AG (AT) | 2012-05-31 | — | — | US | claimed |
| EP-2449488-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES Life Sciences AG (AT) | 2012-05-09 | — | — | EP | claimed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | claimed |
| WO-2011000753-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-01-06 | — | — | WO | claimed |
| EP-2270699-A1 | Method for normalization in metabolomics analysis methods with endogenous reference metabolites | BIOCRATES Life Sciences AG (AT) | 2011-01-05 | — | — | EP | claimed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | claimed |
| EP-2249161-A1 | Method of diagnosing asphyxia | BIOCRATES Life Sciences AG (AT) | 2010-11-10 | — | — | EP | claimed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | disclosed |
| EP-2249161-A1 | Method of diagnosing asphyxia | BIOCRATES Life Sciences AG (AT) | 2010-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | MAPT 1253/4885MEN1 4680/4885KMT2A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.